Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7 ...

Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating ...

The Ultimate Universe took Janet Van Dyne (the Wasp) and turned her into a villain, but it may have saved her life in the process.

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

Tesla shares dipped 4.6% to $303.13 in the pre-market trading session. TaxStatus is the only firm to provide the ...

For some long-time fans, one of the takeaways has been that the Japanese series should return to its roots as a turn-based ...

Dyne Therapeutics, Inc. has announced a $275 million non-dilutive senior secured term loan facility with Hercules Capital, which includes an upfront funding of $100 million and the potential for ...

Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ...

Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.

About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

Investing.com - Bernstein lowered its price target on Dyne Therapeutics (NASDAQ:DYN) to $11.50 from $13.00 on Wednesday, while maintaining a Market Perform rating following the company’s recent ...